SEPSISIII: Sepsis-3 Study in Northeast Thailand

Sponsor
University of Oxford (Other)
Overall Status
Recruiting
CT.gov ID
NCT03379402
Collaborator
Sanpasitthiprasong Hospital (Other), Mahidol Oxford Tropical Medicine Research Unit (Other)
2,700
1
83
32.5

Study Details

Study Description

Brief Summary

This is an observational study to evaluate the utility of the latest recommendation to define severity of infection for sepsis patients (sepsis-3), and to identify the aetiology and factors associated with outcome of community-acquired sepsis in Northeast Thailand.

Potential study participants will be adult patients who are presented at the hospital with community-acquired sepsis. Clinical specimens (including blood, urine, sputum, throat swabs and pus or wound swab) will be collected from each participant on admission for culture, PCR and serological tests, and other laboratory tests. Participants' treatment will be closely monitored during the duration of their hospital stay. Blood will be again collected at 72 hours after admission. Participants will be contacted at 28 days after admission to determine clinical outcome by phone interview with standardized script.

Condition or Disease Intervention/Treatment Phase
  • Other: Specimens collection

Study Design

Study Type:
Observational
Anticipated Enrollment :
2700 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Utility of Sepsis-3 Definition, Causes and Factors Associated With Outcomes in Community-acquired Sepsis in Ubon Ratchathani, Northeast Thailand
Actual Study Start Date :
Feb 1, 2018
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Adult patients presenting with sepsis

Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.

Other: Specimens collection
On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site. Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3.

Outcome Measures

Primary Outcome Measures

  1. 28-day mortality after admission date [2.5 years]

Secondary Outcome Measures

  1. Causative organisms of community-acquired sepsis [2.5 years]

  2. Respiration: Blood gas (PaO2 [mmHg]) [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  3. Respiration: Type of oxygen support [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  4. Respiration: FiO2 (% ) [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  5. Respiration: SpO2 by pulse oximeter level (%) [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  6. Coagulation: Platelet (per μL) [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  7. Liver: Total Bilirubin (mg/dL) [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  8. Cardiovascular: Mean Arterial Pressure (MAP) at enrolment (mmHg) [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  9. Cardiovascular: Dosages (μg/kg/min) of inotropic [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  10. Cardiovascular: Dosages (μg/kg/min) of vasopressor agents [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  11. Central nervous system: Glasgow Coma Score [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  12. Renal: Creatinine (mg/sdL) [2.5 years]

    Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)

  13. Hematology [2.5 years]

    Other laboratory measurement

  14. Blood chemistry [2.5 years]

    Other laboratory measurement

  15. Causes of sepsis associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand [2.5 years]

  16. Sepsis resuscitation associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand [2.5 years]

  17. Antimicrobial treatment associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand [2.5 years]

  18. Inflammatory associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand [2.5 years]

  19. Genetics factors with mortality outcome in patients with community-acquired sepsis in northeast Thailand [2.5 years]

  20. Diagnostic tests for infection in community-acquired sepsis in NE Thailand [2.5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. Males and females 18 years old.

  2. Thai nationality.

  3. Required hospitalization as decided by the attending physician

  4. Documented by attending physician that an infection is the primary cause of illness leading to the hospitalization. These can be infections due to any pathogens (bacteria, viruses, fungi and parasites).

  5. qSOFA (quick Sepsis-related Organ Failure Assessment) score ≥ 2 defined as 2 or more of the following:

  • Respiratory rate ≥22 /min or required ventilator

  • Alteration of mental status (GCS<15 or 10T with endotracheal tube)

  • Systolic blood pressure ≤100 mm Hg

Exclusion Criteria:
  1. Infection is not suspected to be a primary cause of the current illness episode leading to the hospitalization. For example, community-acquired sepsis is considered to be due to stroke, cardiovascular diseases, acute myocardial infarction, cancer, burn, injury, and trauma.

  2. Hospitalized at the study site for this current episode for more than 24 hours before enrollment.

  3. Hospitalized for this current episode for more than 72 hours at another primary/referring hospital

  4. Prior to this current episode, the patient was admitted to any hospital within the last 30 days.

  5. Prior to enrolment, it is documented by the attending physician that hospital acquired infection is associated with the cause of sepsis.

Please note that the following conditions are not exclusion criteria, and patients with the following conditions can be enrolled into the study.

  • Confirmed diagnosis by any method of an infection as a major cause of illnesses leading to hospitalization. For example, a patient who already has had a definite diagnosis of malarial infection by blood smear.

  • Clinical diagnosis of any specific disease or any specific syndromes such as acute infective diarrhea, acute pneumonia, acute encephalomyelitis and acute myocarditis.

  • Suspected of having both infectious and non-infectious diseases and infectious disease is a primary cause of illnesses (primary diagnosis) leading to the hospitalization. For example, acute pneumonia with stroke as an underlying disease, etc.

  • Patients who are admitted to other hospitals and referred to the study site. For example a referred patient who admit to the first hospital less than 24 hours prior to enrollment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sappasithiprasong Hospital Ubon Ratchathani Thailand 34000

Sponsors and Collaborators

  • University of Oxford
  • Sanpasitthiprasong Hospital
  • Mahidol Oxford Tropical Medicine Research Unit

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Oxford
ClinicalTrials.gov Identifier:
NCT03379402
Other Study ID Numbers:
  • HCR17001
First Posted:
Dec 20, 2017
Last Update Posted:
Aug 2, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Oxford
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2022